Antibody infusions prevent acquisition of some HIV strains, studies find

Metoclopramide inhibits proliferation of leukemia stem cells
27 January 2021
Covid-19: NHS must tackle vaccine lies to improve uptake among ethnic minorities, says Stevens
27 January 2021

Antibody infusions prevent acquisition of some HIV strains, studies find

An investigational anti-HIV antibody delivered intravenously once every eight weeks safely and effectively prevented acquisition of HIV strains sensitive to that antibody, but did not significantly reduce overall HIV acquisition after 80 weeks among participants in two multinational clinical trials. Known as the Antibody-Mediated Prevention (AMP) Studies, the Phase 2b trials are sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The studies are being conducted jointly by the HIV Vaccine Trials Network (HVTN) and HIV Prevention Trials Network (HPTN).

Comments are closed.